6f043250-acea-4315-8400-a172214c84c7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 53
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- IL6_JAK_STAT3_SIGNALING+0.410
- ALLOGRAFT_REJECTION+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- HYPOXIA+0.320
- OXIDATIVE_PHOSPHORYLATION+0.300
- COAGULATION+0.290
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.290
- MITOTIC_SPINDLE-0.200
- G2M_CHECKPOINT-0.140
- ANDROGEN_RESPONSE-0.120
- MYC_TARGETS_V1-0.100
- PROTEIN_SECRETION-0.100
- ESTROGEN_RESPONSE_LATE-0.080
- FATTY_ACID_METABOLISM-0.070
- UV_RESPONSE_DN-0.030
- E2F_TARGETS-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1Y2-01A-11R-A157-07 | — | C | 0.893 |
| 2 | TCGA-DK-AA74-01A-11R-A39I-07 | — | — | 0.881 |
| 3 | TCGA-ZF-AA53-01A-11R-A39I-07 | — | — | 0.860 |
| 4 | SRR11296840 | — | — | 0.859 |
| 5 | TCGA-E9-A1NC-01A-21R-A26B-07 | — | E | 0.856 |
| 6 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.856 |
| 7 | SRR12696756 | — | — | 0.851 |
| 8 | MDT-AP-0410 | Med | Medulloblastoma | 0.850 |
| 9 | MDT-AP-2377 | Med | Medulloblastoma | 0.849 |
| 10 | TCGA-35-4123-01A-01R-1107-07 | — | cohortA1 | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |